Real-world Data: Tildrakizumab Restores and Maintains Wellbeing of PsO Patients
Tildrakizumab (Ilumetri, Almirall) restores the level of wellbeing of patients with moderate-to-severe plaque psoriasis to that of the general population as early as Week 16 after initiating the treatment, according to new data from the POSITIVE real-world study. This fundamental benefit was maintained for up to 1 year of treatment. These results were presented at the International Federation […]